Hims & Hers Stock Plummets. The Wegovy Shortage Is Over.
The telehealth company has been selling a copycat version of a popular obesity drug during the recent shortage.
SchaeffersResearch.com3h
Hims and Hers Stock Drops Weight as Earnings Loom
Healthcare stock Hims and Hers (HIMS) is sharply lower today but has contrarian potential next week ahead of earnings ...
Hims & Hers Acquires US-based Peptide Facility
Hims & Hers Health, Inc., the leading health and wellness platform, today announced an acquisition that will further verticalize the company’s long-term ability to deliver personalized medications.
Hims & Hers to offer at-home blood draws, lean into 'peptide innovations' with new acquisitions
The startup is expanding its services less than one year after it started offering compounded GLP-1 weight loss drugs.
Hims & Hers plunges as the FDA says Novo’s weight loss drugs are not in shortage
Hims & Hers Health (HIMS) stock falls as the FDA declares that Novo Nordisk's (NVO) weight loss therapies are no longer in ...
Hims & Hers Health Shares Tumble After Novo Nordisk Says Wegovy, Ozempic Shortage is Over
Shares tumbled 21% to $52.22. Over the last year, the stock has surged more than 450%.
Novo Nordisk up 6%, Hims & Hers down 15% as FDA says Ozempic shortage over
Shares of Novo Nordisk (NVO) are up 6% in pre-market trading after a FDA drug shortage notice indicated that a shortage of several versions of ...
Hims & Hers Crashes 22%--But Its Secret Power Move Could Change Everything
The FDA just slammed the door on its booming weight-loss drug business--but Hims & Hers has a bold new strategy.